Clinical Significance of IL-17 and Foxp3 Expression in Peripheral Blood and Tumor Tissues in Patients with Oral Squamous Cell Carcinoma
-
摘要: 目的 探讨口腔鳞癌患者外周血及癌组织中IL-17和Foxp3的表达及意义。方法 选取40例原发初诊经病理证实的口腔鳞状细胞癌患者为实验对象，术前流式细胞术测定外周血中IL-17与Foxp3所占比例及CD3、CD4、CD8、CD56的表达。组织标本为术中立即取材，SP法测定IL-17及Foxp3表达。选取20例良性肿瘤患者瘤旁正常口腔黏膜作组织对照。实验分为A（Ⅰ、Ⅱ期鳞癌患者）、B（Ⅲ、Ⅳ期鳞癌患者）、C（健康者）三组进行组间比较。 结果 A、B组外周血CD4+IL-17+ 细胞、CD4+Foxp3+细胞所占比例均显著高于C组， IL-17+、Foxp3+的表达水平呈正相关（r=0.772，P<0.05），其中B组CD4+IL-17+、CD4+Foxp3+细胞所占比例高于A组（P<0.05）。与C组相比，A、B组外周血中CD3+和CD4+细胞的百分率、CD4+/CD8+的比值降低，CD8+细胞的百分率升高，差异均有统计学意义（P<0.05）。 IL-17、Foxp3在A、B组中阳性率均明显高于C组，在A组中阳性表达率低于B组，差异均有统计学意义（P<0.05），且A、B组癌组织中IL-17与Foxp3的表达水平呈正相关（r=0.386，P<0.05）。结论 IL-17及Foxp3在口腔鳞癌的发生发展中起着一定的促进作用，这种作用可能与机体免疫状态有关。Abstract: Objective To investigate the expression of IL-17 and Foxp3 in peripheral blood and tumors tissues in patients with oral squamous cell carcinoma(OSCC) and their clinical significance. Methods The cancer tissues from 40 patients with primary OSCC confirmed pathologically were selected. They were compared with the normal mucosal epithelial tissues of 20 patients with benign oral tumor. We collected peripheral blood specimens of experimental group and control group before operation. The proportion of IL-17 and Foxp3 in peripheral blood, and the expression of CD3, CD4, CD8 and CD56 were detected by flow cytometry. The expression of IL-17 and Foxp3 were determined by SP method of immunohistochemistry in the tissues from surgical specimens of experimental group and control group. The objects were divided into Group A(stage Ⅰ, Ⅱ), Group B(stage Ⅲ, Ⅳ)and Group C(normal). Results Compared with Group C, peripheral blood from patients in Group A and B showed higher quantification of CD4+IL-17+ cells and CD4+Foxp3+ cells concentration. IL-17 quantification in peripheral blood from patients with OSCC showed positive correlation with Foxp3 concentration (r=0.772, P<0.05). Compared with Group C, there were obvious differences in declining percentage of CD3+ and CD4+ cells, declining ratio of CD4+/CD8+, and increasing percentage of CD8+ cells in Group A and B(P<0.05). The positive expression rates of IL-17 and Foxp3 in the tissues from Group B were obviously higher than those from Group A; moreover, those from Group A and B were obviously higher than those from Group C(P<0.05). IL-17 quantification in OSCC tissues showed positive correlation with Foxp3 concentration in Group A and B(r=0.386, P<0.05). Conclusion IL-17 and Foxp3 may promote the development and progression of OSCC, and this effect probably is associated with body immune status.
-
-
[1] Lohr J, Knoechel B, Wang JJ, et al. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease[J]. J Exp Med, 20 06, 203(13): 2785-91. [2] Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin(IL)-l in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis[J]. J Exp Med, 2006, 20 3(7): 1685-91. [3] Ma HB, Zhu SB, Liu RM, et al. The expression of Foxp3 in lung cancer cell and its significance[J]. Mian Yi Xue Za Zhi, 2012, 28 (2): 112-5.[马红冰, 朱诗白, 刘瑞敏, 等. 转录因子Foxp3在肺 癌细胞的表达及其意义[J]. 免疫学杂志, 2012, 28(2): 112-5.] [4] Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3[J]. Nat Immunol, 2007, 8(3): 27 7-84. [5] Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression[J]. Nature, 20 07, 445(7129): 766-70. [6] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-70. [7] Mantovani A, Romero P, Palucka AK, et al. Tumour immunity: effector response to tumour and role of the microenvironment[J]. Lancet, 2008, 371(9614): 771-83. [8] Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3[J]. Science, 2003, 29 9(5609): 1057-61. [9] Tian Y, Wu YZ, Ni B. Research progress in the regulation of Foxp3 expression[J]. Mian Yi Xue Za Zhi, 2010, 26(9): 823-6. [田 易, 吴玉章, 倪兵. Foxp3表达调控的研究进展[J]. 免疫学杂志, 20 10, 26(9): 823-6.] [10] Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma[J]. Cancer Res, 2010, 70(20): 77 88-99. [11] Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin17[J]. Nat Immunol, 2005, 6(11): 1133-41. [12] Izcue A, Hue S, Buonocore S, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis[J]. Inmunity, 2008, 28(4): 559-70. [13] Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10[J]. Cancer Immunol Immunother, 2007, 56(1): 48-59. [14] Wang WW, Wang ZM, Liu YY, et al. Increased 1evel of Thl7 cells in peripheral blood correlates with the development of hepatocellular carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2010, 32 (10): 757-61. [王维维, 王振猛, 刘耀阳, 等. 肝细胞癌患者外 周血Thl7细胞水平的变化及其与肿瘤进展的关系[J]. 中华肿瘤 杂志, 2010, 32(10): 757-61.]
计量
- 文章访问数: 1330
- HTML全文浏览量: 329
- PDF下载量: 294
下载:
